Garth W. Strohbehn

Medicine · University of Michigan

Mid career · publishing since 2009

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Economic and Financial Impacts of Cancer Health Systems, Economic Evaluations, Quality of Life COVID-19 Clinical Research Studies

Publications

Citations

2,369

Est. group size

~11

Recurring co-author estimate

Active years

Publishing since 2009

In context

Among 4,491 mid career Medicine PIs within our index

Citations: 2,369cohort median 614

Publications / year (recent): 9.0cohort median 3.4

Typically publishes in teams of ~6 · 40% small-team papers (≤3 authors) · across 33 venues

Publication cadence

Publications per year over the last 10 years — averaging 9.0/year recently

Collaborators per year

Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.

Recent publications

Zanzalintinib as Cabozantinib's Successor: The Case for Skepticism
JCO oncology advances. · 2026
Ivonescimab: The Next United States Food and Drug Administration Project Optimus Flashpoint?
JTO Clinical and Research Reports · 2026
Heterogeneous survival impact of immune-related adverse events in US veterans
Journal for ImmunoTherapy of Cancer · 2026
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority
Clinical and Translational Science · 2025
Non-inferiority trials: tyranny or good governance? – Authors' reply
The Lancet Oncology · 2025
Missed Opportunity for Sotorasib Dose Optimization
Journal of Clinical Oncology · 2025
Introduction of an immunotherapy stewardship program at a single VA medical center.
JCO Oncology Practice · 2025
The tyranny of non-inferiority trials
The Lancet Oncology · 2024
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent
Nature Reviews Clinical Oncology · 2024
Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders
Nature Reviews Clinical Oncology · 2024
Time and Financial Toxicity Implications during Consideration of Pembrolizumab Infusion Frequency
International Journal of Radiation Oncology*Biology*Physics · 2024
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
European Journal of Cancer · 2023
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions
JCO Oncology Practice · 2023
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression
Clinical Lung Cancer · 2023
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy
Annals of Oncology · 2023

Publishes in

Journal of Clinical Oncology×6
Clinical Pharmacology & Therapeutics×5
The Lancet Oncology×5
JCO Oncology Practice×4
International Journal of Radiation Oncology*Biology*Physics×4

Similar researchers

By research-topic overlap

Yan Han
Medicine · Indiana University
Jing Liang
Medicine · The Ohio State University
Kai He
Medicine · The Ohio State University
Kevin Ho
Medicine · The Ohio State University
Jinesh Gheeya
Medicine · The Ohio State University

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 25, 2026.

Claim or correct this profile